Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0TPXRP)
| ADC Name |
sofetabart mipitecan
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
sofetabart mipitecan; MBK-103; LY4170156
Click to Show/Hide
|
|||||
| Organization |
Mablink Bioscience (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Sofetabart
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-Polysarcosine10-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
mipitecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Colorectal cancer | ||||
| Pancreatic cancer | ||||
| Lung cancer | ||||
| Peritoneal cancer | ||||
| Breast cancer | ||||
| Ovarian cancer | ||||
| Fallopian tube cancer | ||||
| Endometrial cancer | ||||
| Cervical cancer |